InvestorsHub Logo
icon url

djmurdock

08/08/16 3:50 PM

#72895 RE: XenaLives #72891

"Goal was to establish dosage and safety for a larger trial - done!"

Exactly....I think this point needs to be harped on more. The fact 2-73 is safe is hugeeeeeee! We should have been green on that aspect alone. So many of these in trial drugs have major negative side affects.
icon url

plexrec

08/08/16 4:00 PM

#72896 RE: XenaLives #72891

Xena--you are so right !!!! Guess we need some positive PR to get the stock moving--come'on Doc--we're waiting !!!!!
icon url

iandy

08/08/16 4:37 PM

#72905 RE: XenaLives #72891

WORLD'S FIRST DOCUMENTED DISEASE REVERSAL IN ALZHEIMER'S



I believe you are overstating the case a bit.

Are you extrapolating the reported encouraging evidence that previously reported positive trends in certain cognitive and biologic measures persisted over a period of approximately 31 weeks to mean the the drug has been proven to reverse cognitive decline?
Are you refering to the reports of patients doing well on the drug?
The analysis of this trial was based on pooled data from a relatively small number of subjects receiving a variety of doses. There is no way a scientist can make definitive statements on any drug related improvement based on this trial - period.

There have been a number of treatments in the past that have reported dramatic improvements:

Novel Drug Therapy Immediately Reverses Alzheimer’s Cognitive Deficits

http://www.lifeextension.com/magazine/2008/8/novel-drug-therapy-immediately-reverses-alzheimers-cognitive-deficits/page-01

Memory loss associated with Alzheimer’s reversed for first time

http://newsroom.ucla.edu/releases/memory-loss-associated-with-alzheimers-reversed-for-first-time

Small Test with Ten Alzheimer's Patients Shows Program Reversed Early Cognitive decline, Improved Symptoms

https://alzheimersnewstoday.com/2016/06/21/multidisciplinary-program-reversed-early-cognitive-decline-dramatically-improving-cognition/

Clinical trial of Alzheimer’s disease drug shows clear reductions in AD development

https://www.ucl.ac.uk/media/library/alzheimers